Science Corner with David Friedberg: GLP-1 Study Shows Encouraging Results

Summary

In this All-In Science Corner segment, David Friedberg presents a new study built on anonymized VA medical records that compares 1.2 million untreated diabetics with about 215,000 patients on GLP-1 receptor agonists and 600,000 on other diabetes drugs. The data show lower hazard ratios across serious conditions, including roughly a 30% lower probability of cardiac arrest plus less shock, hepatic and respiratory failure and schizophrenia, while the only elevated risks are gastrointestinal and musculoskeletal. Friedberg attributes the effects to a gene-expression cascade rather than appetite suppression alone, cites Eli Lilly trials running on additional indications, and names muscle and bone-density loss as the main downside. The group then discusses protocol overload in consumer health, with Chamath arguing GLP-1 products keep growing because one pill removes that cognitive load.

• Anonymized VA medical records used to compare GLP-1 users against untreated and other-drug diabetes cohorts.
• GLP-1 cohort showed lower hazard ratios for cardiac arrest (about 30%), shock, hepatic and respiratory failure and schizophrenia.
• Only elevated risks were gastrointestinal and musculoskeletal: nausea, vomiting, reflux, indigestion and sleep disturbance.
• Friedberg attributes the benefits to a gene-expression cascade that reduces inflammation and increases cellular repair, not appetite suppression alone.
• Eli Lilly is running trials for indications beyond weight loss; phase 2 is published and phase 3 readouts are expected soon.
• Benefits are also appearing in patients who are not obese, separating the drug effect from weight loss itself.
• Muscle loss and bone-density loss cited as the main downside, with protein intake and weightlifting as mitigation.
• Chamath argues fragmented wellness protocols create cognitive load, supporting continued GLP-1 adoption and a coming pill format.